Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of 2-Phenylphenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | HNF4A | P41235 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Phenylphenol SCHEMBL9013767 | 0.96 | ALDH1A1 (0.71) | ALDH1A1HPGDBCL2L1HSD17B10NAPRT | |
| SCHEMBL29876739 | 0.92 | HSD17B10 (0.64) | ALDH1A1HPGDBCL2L1HSD17B10NAPRT | |
| SCHEMBL2038730 | 0.92 | HSD17B10 (0.64) | ALDH1A1HPGDBCL2L1HSD17B10NAPRT | |
| 2-Phenylphenol SCHEMBL27898045 | 0.90 | BCL2L1 (0.63) | ALDH1A1HPGDBCL2L1HSD17B10NAPRT | |
| 2-Phenylphenol SCHEMBL27504029 | 0.87 | ALDH1A1 (0.85) | ALDH1A1HPGDBCL2L1HSD17B10NAPRT | |
| 2-Phenylphenol SCHEMBL2415939 | 0.87 | ALDH1A1 (0.85) | ALDH1A1HPGDBCL2L1HSD17B10NAPRT | |
| Benzoic Acid SCHEMBL9033308 | 0.86 | HNF4A (0.59) | ALDH1A1HPGDBCL2L1HSD17B10NAPRT | |
| SCHEMBL442496 | 0.86 | KMO (0.63) | ALDH1A1HPGDBCL2L1HSD17B10KMO | |
| Hydrochloric Acid SCHEMBL27574419 | 0.85 | KMO (0.61) | ALDH1A1HPGDBCL2L1HSD17B10KMO | |
| Terephthalic Acid SCHEMBL9014425 | 0.85 | TSHR (0.59) | ALDH1A1HPGDBCL2L1HSD17B10NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021011538-A1 | CAPSULE DOSAGE FORMS, METHODS OF PREPARATION AND METHODS OF USE THEREOF | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2021-01-21 | — | — | WO | claimed |
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2024-07-18 | — | — | US | disclosed |
| CN-117986154-A | Antiparasitic compounds | 英特维特国际股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4284509-A1 | ANTIPARASITIC COMPOUNDS | Intervet International B.V. (NL) | 2023-12-06 | — | — | EP | disclosed |
| CN-116964031-A | Antiparasitic compounds | 英特维特国际股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-113166064-B | Cholinesterase inhibitor polymorph and application thereof | 长春华洋高科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-2545777-B2 | Use of an isoxazoline composition as antiparasitic | INTERVET INT BV (NL) | 2023-01-18 | — | — | EP | disclosed |
| US-20220000814-A1 | METHODS FOR TREATMENT OF PRADER-WILLI SYNDROME | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2022-01-06 | — | — | US | disclosed |
| CN-113166064-A | Cholinesterase inhibitor polymorph and application thereof | 长春华洋高科技有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11058652-B2 | Methods for treatment of Prader-Willi syndrome | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-07-13 | — | — | US | disclosed |
| WO-1993024498-A1 | QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM AS WELL AS DENTAL CALCULUS AND PLAQUE | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993024496-A1 | SULFUR-CONTAINING PHOSPONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| US-5260073-A | Use of phenylpropanolamine as a mucus secretogogue in the upper airways | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0530311-A1 | THE USE OF PHENYLPROPANOLAMINE AS A MUCUS SECRETAGOGUE IN THE UPPER AIRWAYS | Norwich-Eaton Pharmaceuticals, Inc. (US) | 1993-03-10 | — | — | EP | disclosed |
| WO-1993004061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004064-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1992016206-A1 | THE USE OF 5-AMINOSALICYLIC ACID IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME - DIARRHEAL PHASE OR TYPE (IBS-D) | NORWICH EATON PHARMACEUTICALS INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016214-A1 | THE USE OF 5-AMINOSALICYLIC ACID IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME - DIARRHEAL PHASE OR TYPE (IBS-D) | NORWICH EATON PHARMACEUTICALS INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1991017746-A1 | THE USE OF PHENYLPROPANOLAMINE AS A MUCUS SECRETAGOGUE IN THE UPPER AIRWAYS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1991-11-28 | — | — | WO | disclosed |
| CN-1047075-A | Luminandide medicine | MILLS RANDELL L (US) | 1990-11-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000814-A1 | METHODS FOR TREATMENT OF PRADER-WILLI SYNDROME | MECP2, BHMT2, EBP | ALDH1A1 3266/4885HPGD 1308/4885BCL2L1 1720/4885 |
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | ALDH1A1 1124/4885HPGD 1883/4885BCL2L1 2728/4885 |
| US-11058652-B2 | Methods for treatment of Prader-Willi syndrome | EBP, MECP2, PRKD3 | ALDH1A1 3154/4885HPGD 1048/4885BCL2L1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.